Nature genetics, ISSN 1061-4036, 2017, Volume 49, Issue 12, pp. 1767 - 1778
Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor...
FUNCTIONAL VARIANTS | COMMON VARIANTS | MODIFIERS | MUTATION CARRIERS | OVARIAN CANCERS | GENETICS & HEREDITY | SUSCEPTIBILITY LOCI | ENHANCER | CONFER SUSCEPTIBILITY | GENOME-WIDE ASSOCIATION | REVEALS | Breast cancer | Genetic aspects | Genetic variation | Health aspects | Risk factors | Disease | BRCA1 protein | Genes | Estrogens | Health risks | Estrogen receptors | Risk | Genomes | Carriers | Consortia | Cell cycle | Breast | Hormone replacement therapy | Mutation | Gene mapping | Health risk assessment | Bioinformatics | Cancer | Medical and Health Sciences | Medicin och hälsovetenskap
FUNCTIONAL VARIANTS | COMMON VARIANTS | MODIFIERS | MUTATION CARRIERS | OVARIAN CANCERS | GENETICS & HEREDITY | SUSCEPTIBILITY LOCI | ENHANCER | CONFER SUSCEPTIBILITY | GENOME-WIDE ASSOCIATION | REVEALS | Breast cancer | Genetic aspects | Genetic variation | Health aspects | Risk factors | Disease | BRCA1 protein | Genes | Estrogens | Health risks | Estrogen receptors | Risk | Genomes | Carriers | Consortia | Cell cycle | Breast | Hormone replacement therapy | Mutation | Gene mapping | Health risk assessment | Bioinformatics | Cancer | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Nature genetics, ISSN 1061-4036, 2017, Volume 49, Issue 5, pp. 680 - 691
To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping...
BREAST-CANCER | COMMON VARIANTS | METAANALYSIS | CLEAR-CELL | ALGORITHM | GENETICS & HEREDITY | RISK | ASSOCIATION | CARCINOMA | ENDOMETRIOSIS | TELOMERE LENGTH | Neoplasms, Glandular and Epithelial - pathology | Genetic Predisposition to Disease - genetics | Genome-Wide Association Study | Meta-Analysis as Topic | Humans | Risk Factors | Genetic Loci - genetics | Ovarian Neoplasms - pathology | Genotype | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Telomere-Binding Proteins - genetics | Alleles | Carcinoma, Ovarian Epithelial | Female | Polymorphism, Single Nucleotide | Mutation | BRCA2 Protein - genetics | Genetic susceptibility | Physiological aspects | Genetic aspects | Single nucleotide polymorphisms | Identification and classification | Health aspects | Risk factors | Ovarian cancer | Carriers | Medical research | Ovarian carcinoma | Genes | Gene regulation | Genomes | Breast cancer | Loci | Cancer | Life Sciences | Human health and pathology | Genetics | Medical and Health Sciences | Medicin och hälsovetenskap
BREAST-CANCER | COMMON VARIANTS | METAANALYSIS | CLEAR-CELL | ALGORITHM | GENETICS & HEREDITY | RISK | ASSOCIATION | CARCINOMA | ENDOMETRIOSIS | TELOMERE LENGTH | Neoplasms, Glandular and Epithelial - pathology | Genetic Predisposition to Disease - genetics | Genome-Wide Association Study | Meta-Analysis as Topic | Humans | Risk Factors | Genetic Loci - genetics | Ovarian Neoplasms - pathology | Genotype | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Telomere-Binding Proteins - genetics | Alleles | Carcinoma, Ovarian Epithelial | Female | Polymorphism, Single Nucleotide | Mutation | BRCA2 Protein - genetics | Genetic susceptibility | Physiological aspects | Genetic aspects | Single nucleotide polymorphisms | Identification and classification | Health aspects | Risk factors | Ovarian cancer | Carriers | Medical research | Ovarian carcinoma | Genes | Gene regulation | Genomes | Breast cancer | Loci | Cancer | Life Sciences | Human health and pathology | Genetics | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
JAMA, ISSN 0098-7484, 01/2006, Volume 295, Issue 2, pp. 180 - 189
CONTEXT Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe. To date, no single international database has...
GLOBAL BURDEN | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | QUALITY | WAIST CIRCUMFERENCE | MYOCARDIAL-INFARCTION | OVERWEIGHT | ATHEROSCLEROSIS | BODY-MASS INDEX | ACUTE CORONARY SYNDROMES | BMI | Prevalence | Global Health | Humans | Middle Aged | Risk Factors | Cardiovascular Diseases - therapy | Male | Thrombosis - epidemiology | Atherosclerosis - epidemiology | Drug Utilization | Outpatients | Atherosclerosis - therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cardiovascular Diseases - epidemiology | Female | Registries | Aged | Platelet Aggregation Inhibitors - therapeutic use | Thrombosis - therapy | Care and treatment | Atheroembolism | Cardiovascular diseases | Risk factors | Blood vessels | Cardiovascular disease | Medical treatment
GLOBAL BURDEN | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | QUALITY | WAIST CIRCUMFERENCE | MYOCARDIAL-INFARCTION | OVERWEIGHT | ATHEROSCLEROSIS | BODY-MASS INDEX | ACUTE CORONARY SYNDROMES | BMI | Prevalence | Global Health | Humans | Middle Aged | Risk Factors | Cardiovascular Diseases - therapy | Male | Thrombosis - epidemiology | Atherosclerosis - epidemiology | Drug Utilization | Outpatients | Atherosclerosis - therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cardiovascular Diseases - epidemiology | Female | Registries | Aged | Platelet Aggregation Inhibitors - therapeutic use | Thrombosis - therapy | Care and treatment | Atheroembolism | Cardiovascular diseases | Risk factors | Blood vessels | Cardiovascular disease | Medical treatment
Journal Article
The Lancet, ISSN 0140-6736, 09/2003, Volume 362, Issue 9386, pp. 782 - 788
Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and...
SURVIVAL | MEDICINE, GENERAL & INTERNAL | ACE | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | HYPERTENSION | EXPRESSION | CONVERTING-ENZYME-INHIBITORS | BLOOD-PRESSURE | CAPTOPRIL | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Treatment Outcome | Cause of Death | Coronary Disease - mortality | Heart Failure - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Heart Arrest - prevention & control | Cardiovascular Diseases - mortality | Coronary Disease - drug therapy | Female | Myocardial Infarction - prevention & control | Perindopril - therapeutic use | Evaluation | Drug therapy | ACE inhibitors | Coronary heart disease | Cardiovascular agents | Cardiovascular disease | Heart attacks | Medical treatment | Morbidity | Clinical outcomes | Myocardial infarction | Risk | Subgroups | Reduction | Motivation | Peptidyl-dipeptidase A | Gangrene | Cardiology | Heart diseases | Heart failure | Hypertension | Stroke | Risk groups | Mortality | Coronary artery | Health risks | Risk reduction | Angina pectoris | Coronary artery disease | Disease control | Patients | Heart rate | Inhibitors | Coronary vessels | Angiotensin | Infarction | Diabetes | Ventricle | Cardiovascular diseases | Health risk assessment | Potassium
SURVIVAL | MEDICINE, GENERAL & INTERNAL | ACE | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | HYPERTENSION | EXPRESSION | CONVERTING-ENZYME-INHIBITORS | BLOOD-PRESSURE | CAPTOPRIL | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Treatment Outcome | Cause of Death | Coronary Disease - mortality | Heart Failure - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Heart Arrest - prevention & control | Cardiovascular Diseases - mortality | Coronary Disease - drug therapy | Female | Myocardial Infarction - prevention & control | Perindopril - therapeutic use | Evaluation | Drug therapy | ACE inhibitors | Coronary heart disease | Cardiovascular agents | Cardiovascular disease | Heart attacks | Medical treatment | Morbidity | Clinical outcomes | Myocardial infarction | Risk | Subgroups | Reduction | Motivation | Peptidyl-dipeptidase A | Gangrene | Cardiology | Heart diseases | Heart failure | Hypertension | Stroke | Risk groups | Mortality | Coronary artery | Health risks | Risk reduction | Angina pectoris | Coronary artery disease | Disease control | Patients | Heart rate | Inhibitors | Coronary vessels | Angiotensin | Infarction | Diabetes | Ventricle | Cardiovascular diseases | Health risk assessment | Potassium
Journal Article
The European Physical Journal C, ISSN 1434-6044, 6/2019, Volume 79, Issue 6, pp. 1 - 161
We review the physics opportunities of the Future Circular Collider, covering its e+e-, pp, ep and heavy ion programmes. We describe the measurement...
Nuclear Physics, Heavy Ions, Hadrons | Measurement Science and Instrumentation | Nuclear Energy | Quantum Field Theories, String Theory | Physics | Elementary Particles, Quantum Field Theory | Astronomy, Astrophysics and Cosmology | TRANSVERSE-MOMENTUM | BRANCHING FRACTIONS | ELECTROWEAK PHASE-TRANSITION | BY-LIGHT SCATTERING | TOP-QUARK | DEEP INELASTIC-SCATTERING | E(+)E(-) COLLISIONS | DARK-MATTER | RADIATIVE-CORRECTIONS | STRANGE BARYON PRODUCTION | PHYSICS, PARTICLES & FIELDS | Àrees temàtiques de la UPC | Física | INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND TECHNOLOGY | PARTICLE ACCELERATORS | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS | Fysik | Physical Sciences | Subatomic Physics | Naturvetenskap | Acceleratorfysik och instrumentering | Subatomär fysik | Accelerator Physics and Instrumentation | Natural Sciences
Nuclear Physics, Heavy Ions, Hadrons | Measurement Science and Instrumentation | Nuclear Energy | Quantum Field Theories, String Theory | Physics | Elementary Particles, Quantum Field Theory | Astronomy, Astrophysics and Cosmology | TRANSVERSE-MOMENTUM | BRANCHING FRACTIONS | ELECTROWEAK PHASE-TRANSITION | BY-LIGHT SCATTERING | TOP-QUARK | DEEP INELASTIC-SCATTERING | E(+)E(-) COLLISIONS | DARK-MATTER | RADIATIVE-CORRECTIONS | STRANGE BARYON PRODUCTION | PHYSICS, PARTICLES & FIELDS | Àrees temàtiques de la UPC | Física | INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND TECHNOLOGY | PARTICLE ACCELERATORS | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS | Fysik | Physical Sciences | Subatomic Physics | Naturvetenskap | Acceleratorfysik och instrumentering | Subatomär fysik | Accelerator Physics and Instrumentation | Natural Sciences
Journal Article
The European Physical Journal. C, Particles and Fields, ISSN 1434-6044, 06/2019, Volume 79, Issue 6, pp. 1 - 161
We review the physics opportunities of the Future Circular Collider, covering its e+e-, pp, ep and heavy ion programmes. We describe the measurement...
Standard model (particle physics) | Quarks | Heavy ions | Physics
Standard model (particle physics) | Quarks | Heavy ions | Physics
Journal Article
British journal of cancer, ISSN 0007-0920, 2012, Volume 106, Issue 12, pp. 2016 - 2024
BACKGROUND: The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer...
MTHFR 677 C>T polymorphism | BRCA1/2 mutation carriers | breast/ovarian cancer risk | PHB 1630 C>T polymorphism | RNA | SUSCEPTIBILITY | METHYLENETETRAHYDROFOLATE REDUCTASE MTHFR | PROHIBITIN 3'-UNTRANSLATED REGION | COMMON MUTATION | MTHFR 677 C > T polymorphism | PHB 1630 C > T polymorphism | CARCINOGENESIS | GENE | CHROMOSOME-17 | ONCOLOGY | FOLATE STATUS | EXPRESSION | Genetic Predisposition to Disease | Humans | Repressor Proteins - genetics | Risk | Polymorphism, Genetic | Ovarian Neoplasms - genetics | Breast Neoplasms - genetics | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Genes, BRCA2 | Female | Heterozygote | Genes, BRCA1 | Mutation | Genetics and Genomics | BRCA1 | ovarian cancer risk | 2 mutation carriers | breast
MTHFR 677 C>T polymorphism | BRCA1/2 mutation carriers | breast/ovarian cancer risk | PHB 1630 C>T polymorphism | RNA | SUSCEPTIBILITY | METHYLENETETRAHYDROFOLATE REDUCTASE MTHFR | PROHIBITIN 3'-UNTRANSLATED REGION | COMMON MUTATION | MTHFR 677 C > T polymorphism | PHB 1630 C > T polymorphism | CARCINOGENESIS | GENE | CHROMOSOME-17 | ONCOLOGY | FOLATE STATUS | EXPRESSION | Genetic Predisposition to Disease | Humans | Repressor Proteins - genetics | Risk | Polymorphism, Genetic | Ovarian Neoplasms - genetics | Breast Neoplasms - genetics | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Genes, BRCA2 | Female | Heterozygote | Genes, BRCA1 | Mutation | Genetics and Genomics | BRCA1 | ovarian cancer risk | 2 mutation carriers | breast
Journal Article
8.
Full Text
FCC-hh: The Hadron Collider: Future Circular Collider Conceptual Design Report Volume 3
European Physical Journal-Special Topics, ISSN 1951-6355, 2019, Volume 228, Issue 4, pp. 755 - 1107
In response to the 2013 Update of the European Strategy for Particle Physics (EPPSU), the Future Circular Collider (FCC) study was launched as a world-wide...
CERN | ENERGY | IMPACT | TOP-QUARK | REDUCTION | PHYSICS, MULTIDISCIPLINARY | MULTIPLE-SCATTERING | Física de partícules | Partícules (Física nuclear) | Particles (Nuclear physics) | Àrees temàtiques de la UPC | Física | PARTICLE ACCELERATORS | Fysik | Physical Sciences | Subatomic Physics | Naturvetenskap | Acceleratorfysik och instrumentering | Subatomär fysik | Accelerator Physics and Instrumentation | Natural Sciences
CERN | ENERGY | IMPACT | TOP-QUARK | REDUCTION | PHYSICS, MULTIDISCIPLINARY | MULTIPLE-SCATTERING | Física de partícules | Partícules (Física nuclear) | Particles (Nuclear physics) | Àrees temàtiques de la UPC | Física | PARTICLE ACCELERATORS | Fysik | Physical Sciences | Subatomic Physics | Naturvetenskap | Acceleratorfysik och instrumentering | Subatomär fysik | Accelerator Physics and Instrumentation | Natural Sciences
Journal Article